Okyanos Heart Institute to Participate in American College of Cardiology Legislative Conference
Chief Medical Officer Dr. Howard T. Walpole Jr. to Serve as Panelist to Provide Insight on Working with Congressional Leaders for Improvements in Cardiovascular Health
Freeport, Bahamas, The, September 21, 2012 --(PR.com)-- Matt Feshbach, CEO of Okyanos Heart Institute (http://www.okyanos.com/), which brings a new standard of care and a better quality of life to patients with coronary artery disease (CAD) using cardiac cell therapy, has announced that Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, served as a panelist at the American College of Cardiology (ACC) Legislative Conference on Monday, Sept. 10. The conference, took place from Sunday, Sept. 9 through Tuesday, Sept. 11 in Washington, D.C., focusing on pressing issues directly impacting the country’s cardiovascular professionals. Dr. Walpole, along with other leading cardiologists, provided insight on how to influence legislative action, a topic that is more important than ever with the U.S. Supreme Court decision on healthcare reform and the upcoming presidential election. Specifically, Walpole spoke to cardiologists about the importance of proactively supporting legislation that will lead to quality, cost-effective and evidence-based care.
Quotes:
“As a leading cardiologist, Dr. Walpole is an ideal candidate to serve as a panelist at the ACC Legislative Conference and share his expertise with attendees,” said Feshbach. “His participation in this conference exemplifies Okyanos Heart Institute’s commitment to supporting the cardiology community and staying informed on current legislative issues, as we all strive to provide quality and cost-effective treatment options to our patients.”
“It is a pleasure to join my medical peers as a panelist for the ACC Legislative Conference,” said Walpole. “As cardiologists, we must stay up to date on legislative actions that impact our profession, positioning ourselves to be involved in educating legislators, in an effort to make the most informed decisions for the patients we treat. Such efforts enable us to advance the practice of medicine and offer new treatment options, including cardiac adult stem cell therapy, to patients in need.”
New Media Content:
Okyanos Blog:
http://bit.ly/Prsdux
Okyanos LinkedIn page:
http://linkd.in/Prsgqd
Okyanos Facebook page:
http://on.fb.me/TKiXTi
Okyanos Twitter page:
http://bit.ly/OFZPqk
About Okyanos Heart Institute:
Based in Freeport, the Bahamas, the Okyanos Heart Institute is a Center of Excellence (CoE) adhering to U.S. surgical center standards and led by Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac cell therapy. The Okyanos treatment utilizes cardiac cell therapy, a unique blend of stem and regenerative cells to support the growth of new blood vessels and to assist the heart in repairing tissue damaged by heart attack and disease. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. These cells facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, visit http://www.okyanos.com/.
Anjelica Cummings
MMI Public Relations
(919) 233-6600
anjelica@mmipublicrelations.com
http://twitter.com/MMIPR
http://www.mmipublicrelations.com
Quotes:
“As a leading cardiologist, Dr. Walpole is an ideal candidate to serve as a panelist at the ACC Legislative Conference and share his expertise with attendees,” said Feshbach. “His participation in this conference exemplifies Okyanos Heart Institute’s commitment to supporting the cardiology community and staying informed on current legislative issues, as we all strive to provide quality and cost-effective treatment options to our patients.”
“It is a pleasure to join my medical peers as a panelist for the ACC Legislative Conference,” said Walpole. “As cardiologists, we must stay up to date on legislative actions that impact our profession, positioning ourselves to be involved in educating legislators, in an effort to make the most informed decisions for the patients we treat. Such efforts enable us to advance the practice of medicine and offer new treatment options, including cardiac adult stem cell therapy, to patients in need.”
New Media Content:
Okyanos Blog:
http://bit.ly/Prsdux
Okyanos LinkedIn page:
http://linkd.in/Prsgqd
Okyanos Facebook page:
http://on.fb.me/TKiXTi
Okyanos Twitter page:
http://bit.ly/OFZPqk
About Okyanos Heart Institute:
Based in Freeport, the Bahamas, the Okyanos Heart Institute is a Center of Excellence (CoE) adhering to U.S. surgical center standards and led by Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac cell therapy. The Okyanos treatment utilizes cardiac cell therapy, a unique blend of stem and regenerative cells to support the growth of new blood vessels and to assist the heart in repairing tissue damaged by heart attack and disease. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. These cells facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, visit http://www.okyanos.com/.
Anjelica Cummings
MMI Public Relations
(919) 233-6600
anjelica@mmipublicrelations.com
http://twitter.com/MMIPR
http://www.mmipublicrelations.com
Contact
Okyanos Heart Institute
Patty Briguglio
919-233-6600
Patty Briguglio
919-233-6600
Contact
Categories